Indegene Limited (BOM:544172)
657.60
+12.40 (1.92%)
At close: Nov 20, 2026
Indegene Revenue
Indegene had revenue of 11.22B INR in the quarter ending September 30, 2026, with 39.55% growth. This brings the company's total for the last twelve months to 41.31B, up 35.84% year-over-year. In the fiscal year ending March 31, 2026, Indegene had annual revenue of 35.11B with 23.64% growth.
Revenue (ttm)
41.31B
Revenue Growth
+35.84%
P/S Ratio
3.84
Revenue / Employee
8.81M
Employees
4,687
Market Cap
158.43B
Revenue by Segment
Fiscal year ended Mar 31, 2026 See the full Indegene breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 35.11B | 6.71B | 23.64% |
| Mar 31, 2025 | 28.39B | 2.50B | 9.64% |
| Mar 31, 2024 | 25.90B | 2.84B | 12.29% |
| Mar 31, 2023 | 23.06B | 6.41B | 38.54% |
| Mar 31, 2022 | 16.65B | 6.84B | 69.76% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Sun Pharmaceutical Industries | 616.31B |
| Apollo Hospitals Enterprise | 278.52B |
| Divi's Laboratories | 121.91B |
| Lenskart Solutions | 103.83B |
| Indegene | 41.31B |
| NATCO Pharma | 30.92B |
| Alivus Life Sciences | 26.84B |
| Pfizer | 26.54B |
Indegene News
- 23 days ago - Indegene Transcript: Q2 26/27 - Transcripts
- 23 days ago - Indegene Quarterly report: Q2 2027 - Filings
- 23 days ago - Indegene Slides: Q2 2027 - Filings
- 3 months ago - Indegene Transcript: Q1 26/27 - Transcripts
- 3 months ago - Indegene Quarterly report: Q1 2027 - Filings
- 3 months ago - Indegene Slides: Q1 2027 - Filings
- 5 months ago - Indegene Slides: Investor presentation - Filings
- 6 months ago - Indegene Transcript: Q4 25/26 - Transcripts